Who is eligible for MIPS 465?

All patients undergoing uterine artery embolization for leiomyomas and/or adenomyosis.

Is MIPS 465 the same as MIPS 465?

Yes. CMS uses zero-padded three-digit Quality IDs (465) in official specifications, while clinicians often search for MIPS 465 or Quality ID 465 without the leading zero. Both refer to the same 2026 MIPS quality measure reported through the Quality Payment Program (QPP).

How do I report MIPS Measure 465 in 2026?

MIPS Measure 465 (Quality ID 465) is reported through the Quality Payment Program (QPP) as a MIPS Clinical Quality Measure (CQM) via qualified registry, or Medicare Part B claims where applicable.

Is MIPS 465 a topped-out measure?

No, MIPS 465 is not topped out, meaning there is still meaningful performance variation across clinicians.

Measure ID: MIPS 465|Interventional Radiology|2026 Performance Year

2026 MIPS Measure #465: Uterine Artery Embolization Technique: Documentation of Angiographic Endpoints

The percentage of patients with documentation of angiographic endpoints of embolization AND the documentation of embolization strategies in the presence of unilateral or bilateral absent uterine arteries.

Process – High PriorityInterventional RadiologyAppropriate Treatment

Measure ID:MIPS 465 (Quality ID 465)

Collection:MIPS CQM

Topped Out:No

View CMS Spec ↗

Measure Specification

Eligible Population

All patients, regardless of age

ANDDiagnosis for leiomyomas or adenomyosis

ANDPatient procedure during the performance period

Exclusions

None

Numerator

Number of patients undergoing uterine artery embolization for symptomatic leiomyomas and/or adenomyosis in whom embolization endpoints are documented separately for each embolized vessel AND ovarian artery angiography or embolization performed in the presence of variant uterine artery anatomy.

Reporting Codes

Performance Met:

G9962Embolization endpoints are documented separately for each embolized vessel AND ovarian artery angiography or embolization performed in the presence of variant uterine artery anatomy

Performance Not Met:

G9963Embolization endpoints are not documented separately for each embolized vessel OR ovarian artery angiography or embolization not performed in the presence of variant uterine artery anatomy

VBCA Insights

Why This Measure Matters

Uterine artery embolization treats symptomatic fibroids and adenomyosis by blocking blood flow to abnormal tissue, but success depends on achieving complete embolization and identifying all feeding vessels. This measure ensures you document the embolization endpoint for each vessel and that you've assessed for variant arterial anatomy (like absent uterine arteries). Careful documentation reflects procedural quality and helps identify when ovarian arteries need treatment to prevent recurrence.

VBCA is a CMS-approved Qualified Clinical Data Registry (QCDR) that submits MIPS Measure 465 to the Quality Payment Program (QPP). Practices can report this measure as a MIPS Clinical Quality Measure (CQM) or through qualified registry submission.

🧮MIPS Score Simulator

Estimate only — actual CMS scoring may vary based on reporting method, data completeness, and annual rule updates.

Your Performance Rate:%Benchmarks vary by collection type

💡 Tip: Enter your performance rate to compare MIPS points across all collection types. The same rate can score differently depending on how you submit.

Specialty Measure Sets

Interventional Radiology

Related Measures

Appropriate Treatment

MIPS 006: Coronary Artery Disease (CAD): Antiplatelet Therapy MIPS 052: Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation and Long-Acting MIPS 187: Stroke and Stroke Rehabilitation: Thrombolytic Therapy MIPS 418: Osteoporosis Management in Women Who Had a Fracture MIPS 445: Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG)MIPS 448: Appropriate Workup Prior to Endometrial Ablation

Official Resources

📄 CMS Measure Specification (PDF)🔗 QPP Quality Payment Program

Clinical Rationale

The efficacy of uterine artery embolization is related to incomplete embolization. The two failure mechanisms that contribute are (1.) appropriate vessel selection but insufficient embolization and (2.) incomplete identification of uterine arterial supply. This measure ensures documentation of two important procedural aspects of uterine artery embolization, which are known to be associated with treatment efficacy: (1.

) appropriate embolization endpoints achieved and (2.) delineation of all uterine arterial supply with embolization where possible. Inadequate arterial embolization alone is a known cause of treatment failure. 1 The ovarian arteries often provide an alternate route of arterial supply to the uterus when the uterine artery is occluded or absent; however routine aortography is not recommended when conventional uterine artery anatomy is present.

Clinical Recommendations

Consensus opinion quality improvement document from the Society of Interventional Radiology utilizing the Modified Delphi method, defining consensus as 80% Delphi participant agreement on a value or parameter.1

Implementation Notes

This measure contains one strata defined by a single submission criteria. This measure produces a single performance rate. For the purposes of MIPS implementation, this procedure measure is submitted each time a procedure is performed during the performance period.

Report this measure through VBCA

Our QCDR handles measure selection, data validation, and submission—so you can focus on clinical performance.

Learn About Our QCDR →Talk to Us